FDA panel to consider OTC status for GSK's anti-obesity drug

12/14/2005 | USA Today

An FDA advisory committee has scheduled a meeting for late January to consider whether to recommend over-the-counter status for GlaxoSmithKline's obesity drug Xenical. If the panel makes a positive recommendation, the drug -- which works by blocking some fat from being absorbed -- would be the first prescription anti-obesity drug to be made available OTC.

View Full Article in:

USA Today

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Food Lawyer
Wayzata, MN
Director of Clinical Research
Regenesis Biomedical, Inc.
Scottsdale, AZ
Meridian Health Plan
Detroit, MI
Assistant Vice President - Dental Director
Bridgewater, NJ